NCT02641990已完成1 期
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Crossover Study to Assess the Effect of ITCA 650 on the Pharmacokinetics and Pharmacodynamics of a Combination Oral Contraceptive in Healthy Premenopausal Female Subjects
Intarcia Therapeutics2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2015年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Area under the plasma concentration-time curve at steady state (AUCss) for ethinyl estradiol and levonorgestrel
研究概览
简要总结
A Phase 1, randomized, double-blind, placebo-controlled, crossover study to assess the effect of ITCA 650 on the pharmacokinetics (PK) of once daily administration of Levora® (ethinyl estradiol 0.3 mg (EE) and levonorgestrel 0.15 mg (LNG) in healthy premenopausal female subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women of childbearing potential.
- •Use of a combination oral contraceptive ≥3 months immediately prior to screening.
- •Willing to use an additional adequate method of contraception during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential (WOCBP) include: mechanical products (ie, intrauterine device [IUD]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermicide.
- •Body mass index (BMI) ≥19 and ≤32 kg per meter squared.
- •Weight ≥50 and ≤100 kg.
- •Non-smoker or ex-smoker for >6 months prior to screening (and has stopped using other nicotine products ≥2 weeks prior to screening).
排除标准
- •History of type 1 or type 2 diabetes.
- •Received implanted contraceptives within 6 months prior to screening or injected contraceptives within 12 months prior to screening.
- •History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
- •History of uncontrolled hypertension.
- •History or evidence of acute or chronic pancreatitis.
- •History of liver disease.
- •History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type
- •Poor thyroid, liver, or renal function.
- •Weight loss surgery or requires weight loss medications.
- •History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for 5 years may be included.)
- •Estrogen-dependent growths; undiagnosed vaginal bleeding.
- •History of active alcohol or substance abuse.
- •Regular daily consumption of more than 12 g of alcohol in any form.
- •Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
- •Treatment with medications that affect GI motility.
- •Any condition that would affect drug transit time or absorption (eg, gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue).
- •History of hypersensitivity to exenatide.
- •Contraindications or warnings according to the specific label(s) for EE and/or LNG therapy.
- •Women that are pregnant, lactating, or planning to become pregnant.
- •Any use of anticoagulants with the exception of those given in prophylaxis prior to surgical intervention.
- •History of or positive results on screening tests for hepatitis B and/or hepatitis C and/or human immunodeficiency virus (HIV).
- •Recent surgery or planned in-patient surgery, dental procedure, or hospitalization during the study.
- •History of migraine if aged >35 years or has focal symptoms associated with migraine.
- •History of thrombophlebitis, thromboembolic disorders, or deep vein thrombophlebitis.
- •Fasting triglycerides above upper limit of normal at Screening.
- •Any gastrointestinal complaints within 7 days prior to first dosing.
研究组 & 干预措施
Group 1
Experimental
ITCA 650 20/60 mcg/day, ITCA placebo
干预措施: ITCA 650 20/60 mcg/day, ITCA placebo (Drug)
Group 2
Experimental
ITCA placebo, ITCA 650 20/60 mcg/day
干预措施: ITCA placebo, ITCA 650 20/60 mcg/day (Drug)
结局指标
主要结局
Area under the plasma concentration-time curve at steady state (AUCss) for ethinyl estradiol and levonorgestrel
时间窗: from baseline to 13 weeks
Maximum steady state plasma concentration (Cmax,ss) for ethinyl estradiol and levonorgestrel
时间窗: from baseline to 13 weeks
次要结局
- Time to maximum steady state plasma concentration (tmax,ss) for ethinyl estradiol and levonorgestrel(baseline to 13 weeks)
- Apparent plasma clearance at steady-state (CL/Fss) for ethinyl estradiol and levonorgestrel(baseline to 13 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus SubjectsDiabetes MellitusNCT01755442Amgen5
Unknown
1 期
Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled LipopolysaccharideAcute Inflammatory Response to Non-antigenic StimulusNCT02515396Moerae Matrix, Inc.20
已完成
1 期
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BVL-GSK098 in Healthy VolunteersHealthy VolunteersNCT04654143BioVersys AG80
尚未招募
1 期
Human Umbilical Cord Blood Infusion in Patients with Cerebral PalsyCerebral PalsyNCT06377982StemCyte Taiwan Co., Ltd.12
已完成
1 期
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy VolunteersSafety and TolerabilityNCT05451667Yuejia Pharmaceuticals (USA), Inc.32